Findings

What do systematic reviews say?

8 questions · 8 findings · 6 reviews

Sort:Best matchNewest Highest certainty Download CSV

No studies found 3 · 37.5%GRADE not reported 0 · 0%Very low 0 · 0%Low 1 · 12.5%Moderate 4 · 50%High 0 · 0%

Anti‐VEGF vs control

Quality of life · CNV in people with pathologic myopia

1 finding from 1 review

Anti‐vascular endothelial growth factor for choroidal neovascularisation in people with pathological myopia 2016 · Cochrane Headline outcomes only
no estimate extracted
1 study · 121 participants
Moderate

Radiotherapy combined with anti‐VEGF vs anti‐VEGF alone

Quality of life · people with neovascular AMD

The review found no eligible studies for this question.

1 finding from 1 review

Radiotherapy for neovascular age‐related macular degeneration 2020 · Cochrane Headline outcomes only
no estimate extracted
Studies not reported
No studies found

Anti‐VEGF vs laser

QoL · people with BRVO

The review found no eligible studies for this question.

1 finding from 1 review

Anti‐vascular endothelial growth factor for macular oedema secondary to branch retinal vein occlusion 2020 · Cochrane Headline outcomes only
no estimate extracted
Studies not reported
No studies found

Anti‐VEGF vs steroids

QoL · people with BRVO

1 finding from 1 review

Anti‐vascular endothelial growth factor for macular oedema secondary to branch retinal vein occlusion 2020 · Cochrane Headline outcomes only
no estimate extracted
1 study · 307 participants
Moderate

Anti‐VEGF vs sham

QoL · macular oedema secondary to branch retinal vein occlusion

1 finding from 1 review

Anti‐vascular endothelial growth factor for macular oedema secondary to branch retinal vein occlusion 2020 · Cochrane Headline outcomes only
no estimate extracted
1 study · 281 participants
Moderate

Summary of findings: intravitreal bevacizumab plus intravitreal steroid vs intravitreal anti‐VEGF

Quality of life at · adults with centre‐involving diabetic macular oedema

The review found no eligible studies for this question.

1 finding from 1 review

Anti‐vascular endothelial growth factor combined with intravitreal steroids for diabetic macular oedema 2018 · Cochrane Headline outcomes only
no estimate extracted
Studies not reported
No studies found

Anti‐VEGF vs control

Vision‐related quality of life · people with neovascular age‐related macular degeneration

Summary of findings: anti‐VEGF treatment probably leads to higher mean change in vision‐related quality of life compared with control (moderate certainty).

1 finding from 1 review

Anti‐vascular endothelial growth factor for neovascular age‐related macular degeneration 2019 · Cochrane Headline outcomes only
MD 6.69 [3.38, 9.99]
2 studies · 1134 participants
Moderate

Anti‐vascular endothelial growth factor (anti‐VEGF) with or without pan‐retinal photocoagulation (PRP) vs PRP alone

Quality of life (VFQ‐25 General health) · proliferative diabetic retinopathy

1 finding from 1 review

Anti‐vascular endothelial growth factor for proliferative diabetic retinopathy 2023 · Cochrane Headline outcomes only
no estimate extracted
2 studies · 382 participants
Low